Last updated: 2026-09-21 21:50:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Merck & Co., Inc. (MRK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $149.53, with a market capitalization of $362.35B and a P/E ratio of 114.20. Over the past 52 weeks, its price has ranged from $77.58 to $156.92. This page covers its latest market performance, valuation, price trends and company information.
$362.35B | |
$146.79 | |
$156.92 | |
$15.32 | |
$146.87 | |
5.04M | |
10.20M | |
114.20 | |
$156.92 | |
$77.58 | |
2.29% | |
-- |
Merck & Co., Inc. (MRK) is trading at $149.98 in after-hours trading as of 2026-09-21 21:47:00, up 2.11% ($3.11) from the regular-session close of $146.87.
After-hours trading shows how investors are pricing MRK after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Merck & Co., Inc. (MRK) moved from $144.71 to $149.53, representing a gain of 3.33% ($4.82).
The stock traded between $142.32 and $150.47 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 11.63 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 90.7%
MRK is currently trading at $149.53, placing it 90.7% of the way from its 52-week low of $77.58 to its 52-week high of $156.92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Merck & Co., Inc. (MRK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.